MedTrace Logo

Serum 25-Hydroxyvitamin D and Neurological Disability in Multiple Sclerosis

NCT07123337 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 369

Last updated 2025-08-19

No results posted yet for this study

Summary

Vitamin D is hypothesized to play a role in the immunopathology and progression of multiple sclerosis (MS), yet its association with neurological disability remains uncertain, particularly in North African populations.We conducted a cross-sectional study involving 369 adult MS patients across two tertiary neurology centers in Western Libya. Serum 25-hydroxyvitamin D \[25(OH)D\] levels and Expanded Disability Status Scale (EDSS) scores were collected. Pearson correlation, ANOVA, and multivariable linear regression were used to assess associations between vitamin D and disability, adjusting for age, BMI, disease duration, and physical activity. Missing data and outliers were handled systematically using validated R and Python workflows.

Conditions

Sponsors & Collaborators

  • University of Zintan

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-01
Primary Completion
2025-02-15
Completion
2025-04-08

Countries

  • Libya

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07123337 on ClinicalTrials.gov